We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0375 | -3.04% | 1.195 | 1.155 | 1.235 | 1.195 | 1.12 | 1.125 | 237,119 | 09:07:08 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -2.92M | -0.0070 | -1.70 | 5.13M |
TIDMIMM
RNS Number : 5995L
Immupharma PLC
06 September 2023
TR-1: S tandard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) (i) 1a. Identity of the issuer or the Immupharma plc underlying issuer of existing shares to which voting rights are attached (ii) : -------------------------------------------- 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer ---- 2. Reason for the notification (please mark the appropriate box or boxes with an "X") An acquisition or disposal of voting rights X ---- An acquisition or disposal of financial instruments ---- An event changing the breakdown of voting rights ---- Other (please specify)(iii) : ---- 3. Details of person subject to the notification obligation (iv) Name Lanstead Capital Investors LP City and country of registered office (if applicable) 4. Full name of shareholder(s) (if different from 3.) (v) Name -------------------------------------------- City and country of registered office (if applicable) -------------------------------------------- 5. Date on which the threshold was 05/09/2023 crossed or reached (vi) : -------------------------------------------- 6. Date on which issuer notified 06/09/2023 (DD/MM/YYYY): -------------------------------------------- 7. Total positions of person(s) subject to the notification obligation % of voting % of voting rights Total of both Total number rights attached through financial in % (8.A + of voting rights to shares (total instruments 8.B) of issuer (vii) of 8. A) (total of 8.B 1 + 8.B 2) ------------------ --------------------- -------------- -------------------- Resulting situation on the date on which threshold was crossed or reached 22.28% 0.00% 22.28% 409,903,115 ------------------ --------------------- -------------- -------------------- Position of previous notification (if applicable) 7.97% 0.00% 7.97% ------------------ --------------------- -------------- -------------------- 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached (viii) A: Voting rights attached to shares Class/type of Number of voting rights % of voting rights shares (ix) ISIN code (if possible) Direct Indirect Direct Indirect (Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive 2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC) (DTR5.1) (DTR5.2.1) (DTR5.2.1) -------------------------- Ordinary Shares ISIN: GB0033711010 91,322,252 0 22.28% 0.00% ---------------------- -------------------------- ------------------------- --------------------- SUBTOTAL 8. A 91,322,252 22.28% -------------------------------------------------- ------------------------------------------------ B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) Type of Expiration Exercise/ Number of voting % of voting financial date Conversion Period rights that may rights instrument (x) (xi) be acquired if the instrument is exercised/converted. ----------- ------------------------------ -------------------------------- --------------------- N/A ----------- ------------------------------ -------------------------------- --------------------- SUBTOTAL 8. B 1 ------------------------------ -------------------------------- --------------------- B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) Type of Expiration Exercise/ Physical Number of % of voting financial date (x) Conversion or cash voting rights rights instrument Period (xi) settlement (xii) ---------------- -------------------- -------------------- -------------------- N/A ----------- -------------------- -------------------- -------------------- SUBTOTAL 8.B.2 -------------------- -------------------- 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") Person subject to the notification obligation is not controlled X by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer (xiii) Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (xiv) (please add additional rows as necessary) Name (xv) % of voting rights % of voting rights Total of both if if it equals or through financial it equals or is is higher than the instruments if it higher than the notifiable threshold equals or is higher notifiable threshold than the notifiable threshold ---------------------- --------------------- ------------------------ N/A ---------------------- --------------------- ------------------------ 10. In case of proxy voting, please identify: Name of the proxy holder ----------------------------------------------- The number and % of voting rights held ----------------------------------------------- The date until which the voting rights will be held ----------------------------------------------- 11. Additional information (xvi) Place of completion LON Date of completion 06/09/2023 -----------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
HOLBDGDCGUGDGXL
(END) Dow Jones Newswires
September 06, 2023 08:53 ET (12:53 GMT)
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions